However, despite the development of new TKIs, new mutations in EGFR exon 20, developing resistance to EGFR TKIs, have emerged in the treated NSCLC [6,7], and current therapies are not sufficient to cure or manage the patients with distant metastasis [8,9]. Here, EGFR is linked to non-small cell lung carcinoma.